Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Forbion Capital Partners
Biotech
Sparrow flits forward with $95M for midstage diabetes asset
The Oregon biotech will use the raise for a phase 2b trial of oral small molecule clofutriben in patients with Type 2 diabetes and excess cortisol.
Darren Incorvaia
Sep 24, 2025 11:22am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
MapLight raises $373M to plot phase 2 journey for Cobenfy rival
Jul 28, 2025 10:23am
Versant unveils new autoimmune biotech with $100M fundraise
Apr 24, 2025 8:00am
Forbion's €2B funds are largest yet, with 30 biotechs to benefit
Oct 15, 2024 4:43am
A VC recovery may be coming in Europe: PitchBook
Aug 22, 2024 3:00pm
